Jollpen Injection contains Penicillin G, equivalent to 5 lakh units per dose, a potent beta-lactam antibiotic belonging to the penicillin class. It is indicated for the treatment of a wide range of bacterial infections caused by penicillin-sensitive organisms, including streptococcal, pneumococcal, and staphylococcal infections, as well as infections caused by anaerobic bacteria and certain spirochetes. Penicillin G exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Jollpen Injection is administered via intramuscular or intravenous routes, ensuring rapid systemic absorption and effective plasma concentrations. It is commonly used in conditions such as bacterial endocarditis, syphilis, respiratory tract infections, septicemia, meningitis, and prophylaxis against rheumatic fever. Dosage and duration of therapy should be tailored according to the severity of infection, patient age, renal function, and susceptibility patterns. Caution is advised in patients with a history of hypersensitivity to penicillins or other beta-lactam antibiotics. Adverse reactions may include hypersensitivity reactions, gastrointestinal disturbances, and local injection site reactions. Proper administration and monitoring are essential to maximize therapeutic efficacy and minimize potential adverse effects. Jollpen Injection should be used under medical supervision with adherence to prescribed guidelines.